7 hours Ago By Defense World Staff
Raymond James Financial Inc. bought a new stake in shares of Genmab A/S ( NASDAQ:GMAB – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 118,002 shares of the company’s stock, valued at approximately $2,463,000.
Other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% during the fourth quarter.
EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% during the 4th quarter.
Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC increased its stake in shares of Genmab A/S by 96.6% in the fourth quarter.
GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Cromwell Holdings LLC grew its stake in Genmab A/S by 656.8% in the 4th quarter.
Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after buying an additional 2,496 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of Genmab A/S during the 4th quarter valued at $93,000. Hedge funds and other institutional investors own 7.
07% of the company’s stock. Analyst Upgrades and Downgrades A number of research analysts have weighed in on GMAB shares. Sanford C.
Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.
00 target price on the stock in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.
00 price target (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock.
According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $39.17.
Genmab A/S Stock Up 0.8 % GMAB opened at $20.79 on Wednesday.
The business’s fifty day simple moving average is $20.41 and its 200 day simple moving average is $21.00.
Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41.
The stock has a market cap of $13.76 billion, a PE ratio of 11.95, a P/E/G ratio of 2.
65 and a beta of 1.07. Genmab A/S ( NASDAQ:GMAB – Get Free Report ) last announced its quarterly earnings data on Wednesday, February 12th.
The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.
29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.
30%. As a group, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.
Genmab A/S Profile ( Free Report ) Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Further Reading Five stocks we like better than Genmab A/S 3 Ways To Invest In Coffee, Other Than Drinking It Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Why Invest in High-Yield Dividend Stocks? Coca-Cola Company Stock Can Bubble to New Highs This Year What is a Microcap Stock? Everything You Need to Know 3 Stocks Lifting 2025 Guidance Despite Market Jitters Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Genmab A/S ( NASDAQ:GMAB – Free Report ). Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
